세계의 프로테오믹스 시장 보고서 : 분석 유형, 구성 요소 유형, 기술, 응용 분야, 최종 사용자, 지역별(2024-2032년)

The global proteomics market size reached US$ 36.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 126.2 Billion by 2032, exhibiting a growth rate (CAGR) of 14.4% during 2024-2032.

Proteomics refers to the study of proteomes, their structure and physiological functions on a large-scale. In 1994, Mark Wilkins first coined the term proteome for the proteins that are translated from genome, to denote the whole set of proteins synthesized within a living organism. It encompasses the modifications and alterations that take place in the existing protein when it is exposed to varying conditions. Proteomics applies various technologies for the quantification and identification of proteins, along with the detection of diagnostic markers, understanding of pathogens in cells and interpretation of protein pathways in different diseases. It also evaluates the rate of protein production and the interaction patterns of proteins due to which it finds extensive applicability in drug discovery and the development of personalized medications.

The growing preference for personalized drugs, along with increasing research and development in drug discovery and biotechnology, is the key factor driving the growth of the market. Proteomic systems reduce the time, cost and resources needed for the chemical synthesis and biological testing of drugs and simplify the process of drug discovery. Furthermore, opportunities related to biomarker identification and mass spectrometry-based proteomics are favoring the market growth further. Additionally, the market is driven by increasing technological penetration in the comprehensive analysis of protein techniques. These techniques include Electrospray Ionization-Liquid Chromatography-Mass Spectrometry (ESI-LC-MS), surface plasma resonance, microarray, protein fractionation systems and X-ray crystallography. These advancements enable a thorough quantitative and qualitative analysis of proteins and identification of cancer therapies and treatments. Other factors, such as favorable government policies for extensive research and development (R&D) are also augmenting the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global proteomics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on analysis type, component type, technology, application and end-user.

Breakup by Analysis Type:

Structural Proteomics

Functional Proteomics

Protein Expression Proteomics

Breakup by Component Type:

Core Proteomics Services

Bioinformatics Software and Related Services

Breakup by Technology:

Spectroscopy

Chromatography

Electrophoresis

Protein Microarrays

X-Ray Crystallography

Surface Plasmon Resonance

Others

Breakup by Application:

Protein Expression Profiling

Proteome Mining

Post-translational Modifications

Breakup by End-User:

Clinical Diagnostic Laboratories

Research Organizations (Drug Discovery)

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, GE Healthcare Inc., Horiba Ltd., Luminex Corporation, Merck Group, Perkinelmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., Waters Corporation, etc.

Key Questions Answered in This Report

• 1. How big is the global proteomics market?
• 2. What is the expected growth rate of the global proteomics market during 2024-2032?
• 3. What are the key factors driving the global proteomics market?
• 4. What has been the impact of COVID-19 on the global proteomics market?
• 5. What is the breakup of the global proteomics market based on the technology?
• 6. What is the breakup of the global proteomics market based on the end-user?
• 7. What are the key regions in the global proteomics market?
• 8. Who are the key players/companies in the global proteomics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Proteomics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Analysis Type

• 6.1 Structural Proteomics
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Functional Proteomics
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Protein Expression Proteomics
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Component Type

• 7.1 Core Proteomics Services
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Bioinformatics Software and Related Services
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Technology

• 8.1 Spectroscopy
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Chromatography
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Electrophoresis
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Protein Microarrays
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 X-Ray Crystallography
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Surface Plasmon Resonance
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by Application

• 9.1 Protein Expression Profiling
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Proteome Mining
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Post-translational Modifications
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by End-User

• 10.1 Clinical Diagnostic Laboratories
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Research Organizations (Drug Discovery)
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Others
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Agilent Technologies Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Bio-RAD Laboratories Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Bruker Corporation
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Creative Proteomics
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Danaher Corporation
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 GE Healthcare Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Horiba Ltd.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
  • 15.3.8 Luminex Corporation
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Merck Group
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Perkinelmer Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Promega Corporation
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
  • 15.3.12 Thermo Fisher Scientific Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 Waters Corporation
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio
    • 15.3.13.3 Financials
    • 15.3.13.4 SWOT Analysis